P2Y12抑制剂单疗法:PCI后急性和长期二次预防的考虑
Antonio Greco1, Maria Sara Mauro1, Davide Capodanno1
1Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico - San Marco", 95125 Catania, Italy.
Reviews in cardiovascular medicine
|July 30, 2024
概括
在PCI后的双重抗血小板治疗 (DAPT) 可能会过渡到P2Y12抑制剂单一治疗. 这种方法在不增加缺血事件的情况下降低出血风险,为PCI患者的二次预防提供了更安全的替代方案.
科学领域:
- 心脏病学和干预性心脏病学
- 药理学和治疗学 药理学和治疗学
- 临床证据和指南更新.
背景情况:
- 通过皮肤冠状动脉干预 (PCI) 后,用阿司匹林和P2Y12抑制剂进行双重抗血小板治疗 (DAPT) 是标准的.
- 长期的二次预防通常涉及DAPT后的阿司匹林单疗法.
- 新出现的证据支持P2Y12抑制剂单一治疗在PCI后的急性和慢性环境中.
研究的目的:
- 审查目前关于PCI后二次预防P2Y12抑制剂单疗的证据.
- 评估P2Y12抑制剂单疗与标准抗血小板策略的疗效和安全性.
- 探索P2Y12抑制剂单疗在需要口服抗凝药的患者中的作用.
主要方法:
- 从临床研究和随机试验中对P2Y12抑制剂单一治疗的累积证据的审查.
- 结果分析包括血栓并发症,出血事件和临床净益处.
- 考虑最近欧洲和美国关于抗血栓治疗的指导方针更新.
主要成果:
- 与标准的DAPT相比,短期的DAPT随后的P2Y12抑制剂单疗法显示出减少出血而没有增加缺血事件.
- 长期使用P2Y12抑制剂单一治疗的有限数据表明,与阿司匹林单一治疗相比,这种疗法具有潜在的益处.
- 目前的指导方针将P2Y12抑制剂单疗法纳入特定的PCI后情景.
结论:
- P2Y12抑制剂单疗是一种可行的选择,用于PCI后的早期和长期二次预防,特别是减少出血风险.
- 需要进一步的研究来解决剩余的不确定性,并优化抗血栓策略.
- 目前正在进行的随机试验旨在为P2Y12抑制剂单疗提供更明确的证据.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
505
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
505
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
141
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
141
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
152
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
152
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
659
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
659
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
481
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
481